Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension
Abstract Pulmonary hypertension (PH) is a highly morbid condition. PH due to left heart disease (PH‐LHD) has no specific therapies and pulmonary arterial hypertension (PAH) has substantial residual risk despite several approved therapies. Multiple lines of experimental evidence link metabolic dysfun...
Main Authors: | Nicholas E. King, Evan Brittain |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Pulmonary Circulation |
Subjects: | |
Online Access: | https://doi.org/10.1002/pul2.12028 |
Similar Items
-
Peak steps: Capacity for activity improves after adding approved therapy in pulmonary arterial hypertension
by: Daniel Lachant, et al.
Published: (2023-07-01) -
Novel and emerging therapies in pulmonary arterial hypertension
by: Steven J. Cassady, et al.
Published: (2022-12-01) -
Should We Change the Target of Therapy in Pulmonary Hypertension?
by: Panagiotis Karyofyllis, et al.
Published: (2023-05-01) -
Bosentan therapy for chronic thromboembolic pulmonary hypertension
by: L Huber, et al.
Published: (2007-10-01) -
Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
by: Henry Sutanto, et al.
Published: (2021-08-01)